Moreover, we recently demonstrated through the Genomics of Drug Sensitivity in Cancer (GDSC) high-throughput screen of ∼800 solid tumor cancer cell lines, that navitoclax, the venetoclax predecessor that also inhibits BCL-xL, had activity in a large number of SCLCs and several subgroups of solid tumors [4]. The gene discussed is BCL2L1; the disease is cancer.